A Regulatory Standoff with High Stakes In a move that sent shockwaves through the biotechnology sector, the U.S. Food and Drug Administration (FDA) has taken the extraordinary step of refusing to conduct a formal review of Moderna's biologics license application for its mRNA-based influenza
With the healthcare landscape in constant flux, the latest proposal from the Centers for Medicare & Medicaid Services aims to reshape the Affordable Care Act marketplaces. To help us understand these sweeping changes, we're speaking with James Maitland, a leading expert on U.S. health insurance
A federal policy designed to overhaul a critical drug pricing program for the nation's most vulnerable hospitals was dismantled not by political debate or public outcry, but by a precise legal maneuver that halted its implementation just days before it was set to begin. The swift and total collapse
With the recent launch of the TrumpRx portal, the White House has waded directly into the complex world of pharmaceutical sales, promising lower prices for Americans. To unpack the real-world implications of this move, we're speaking with James Maitland, a leading analyst whose work has
In a significant challenge to the long-criticized practices that drive up prescription drug costs in the United States, the Federal Trade Commission (FTC) has finalized a landmark settlement with Express Scripts, one of the nation’s most powerful pharmacy benefit managers (PBMs). This agreement
A Looming Crisis: Why a New Rate Proposal Has Shaken the Medicare Advantage Landscape For years, Medicare Advantage (MA) has been a cornerstone of American senior healthcare, growing exponentially as a popular private alternative to traditional Medicare. However, the program's seemingly unstoppable
